EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.?EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids.?Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.

HG106, which is anti-inflammatory and may be used to treat the growth of diseases such as malignant tumours caused by mutations in the RAS gene, which is anti-inflammatory and may be used to treat the growth of diseases such as malignant tumours caused by mutations in the RAS gene.

Ternatumoside II is a aqueous extract of Bauhinia megalandra leaves inhibits GIA.